Progenics, Protein Design Labs deal

PDLI will humanize PGNX's PRO 140 anti- CCR5 monoclonal antibody that blocks the fusion of viral and target cell membranes in HIV replication. PGNX will pay PDLI a license and signing fee, milestones...